Tareg (Valsartan) is generally prescribed to provide essential, long-term therapeutic support across three critical cardiovascular domains. This management approach supports efforts aimed at risk reduction and assisting with organ function stability.

The medication plays a role in managing conditions characterized by symptoms related to systemic imbalance, specifically addressing elevated vascular pressure (hypertension), which often creates noticeable physiological strain over time. It is also relevant for managing symptoms that create noticeable physiological strain in chronic heart failure and in clinical settings for the management of the post-myocardial infarction phase when the patient has ventricular dysfunction.

This therapy may assist with supporting improved patient outcomes and may assist with maintaining functional stability to help reduce the impact of the condition. It is commonly used to help with managing chronic high blood pressure, supporting chronic heart failure, and providing post-heart attack cardiovascular protection.

---

Quick Fact: Relief for Elevated Vascular Pressure The goal of this long-term management is to achieve blood pressure control, which supports the patient during difficult episodes and assists with maintaining functional stability.

Regulatory References

1. NIH MedlinePlus Drug Information on Valsartan

Eligibility Map: Who Can and Cannot Use Tareg (Valsartan) — Official Regulatory Information

Eligibility Scope	Regulatory Classification
Populations for whom use is allowed	Adult patients for hypertension, heart failure, and post-myocardial infarction with left ventricular dysfunction. Pediatric patients aged 6 to less than 18 years for hypertension only.
Populations for whom use is contraindicated	Severe hepatic impairment, biliary cirrhosis, and cholestasis. Known hypersensitivity to Valsartan or excipients. Females in the second and third trimesters of pregnancy.
Age-related eligibility rules	Use for hypertension is not recommended in children under 6 years of age. Use for heart failure and post-myocardial infarction is not established in children under 18 years.
Condition-specific eligibility rules	Use requires caution in patients with mild to moderate hepatic impairment. It is contraindicated with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m^2).
Pregnancy and lactation eligibility status	Contraindicated during the second and third trimesters of pregnancy. Not recommended during breastfeeding.

---

Eligibility Classifications (High-Level)

Classification Type	Regulatory Definition
Eligibility severity classification	Contraindicated (absolute prohibition, e.g., pregnancy, severe hepatic impairment); Not Recommended (use should be avoided, e.g., breastfeeding); Caution/Restricted Use (permitted under monitoring, e.g., mild hepatic impairment).
Regulatory basis	EU Summary of Product Characteristics (SmPC) and US FDA Prescribing Information.
Eligibility-context constraints	Exclusion based on specific disease states (severe hepatic conditions) or combination therapy (dual RAAS blockade with Aliskiren).

---

Resulting Eligibility Structure

Official regulatory documents establish the population for Tareg (Valsartan) by creating mandatory exclusions centered on specific comorbidities, such as severe hepatic disease, and physiological states, notably pregnancy. Eligibility is conditionally restricted in patients with volume depletion or mild organ impairment, demanding careful consideration. Furthermore, regulatory labeling explicitly defines age-group limitations, restricting the use for certain cardiovascular indications to only the adult population while permitting hypertension treatment in children aged six and older.

Tareg Interactions with other medicines and products

The official regulatory profile for Tareg (Valsartan) documents several clinically significant interaction categories and formal restrictions, which are defined by government health authorities.

Major Interaction Restrictions and Risks	Interaction Classification	Interacting Substance(s)	Formal Interaction Outcome
Contraindicated Combination	Aliskiren	Prohibited in patients with diabetes mellitus.
Dual RAS Blockade Risk	ACE Inhibitors, Aliskiren	Associated with increased risks of hypotension, hyperkalemia, and renal impairment.

Pharmacodynamic and Exposure-Altering Effects Co-administration with potassium-sparing diuretics (such as spironolactone), potassium supplements, or potassium-containing salt substitutes has a documented additive effect, raising the risk of hyperkalemia (high serum potassium). This pharmacodynamic risk extends to other agents that increase serum potassium, such as Heparin.

Combining Valsartan with Lithium is officially documented to increase serum lithium concentrations and the potential risk of toxicity. This effect is attributed to reduced renal clearance.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may attenuate the antihypertensive effect of Valsartan. This co-administration also increases the risk of deterioration of renal function, a warning specifically noted as heightened for the elderly, volume-depleted, or those with pre-existing renal compromise.

Food has been shown to decrease the absorption of Valsartan, while alcohol may contribute to the blood pressure-lowering effect.

Tareg is an agent that modulates the bone remodeling process through a targeted action on the skeletal system. The mechanism of action involves inhibiting the Receptor Activator of NF-kappaB Ligand (RANKL), a protein essential for osteoclastogenesis and bone resorption.

By binding directly to RANKL, Tareg prevents its interaction with the RANK receptor located on the surface of pre-osteoclasts and mature osteoclasts. This blockade suppresses osteoclast formation, function, and survival. The resultant downstream mechanistic cascade includes decreased signaling through the NF-kappaB and JNK pathways within the osteoclast precursor, leading to a net reduction in bone tissue breakdown and continuous modulation of bone turnover.

Valsartan (Tareg) is an oral medication with specific administration guidelines that define its clinical use based on the condition being addressed. The official approved administration route is oral, available as film-coated tablets in strengths up to 320 mg, as well as a liquid oral suspension (e.g., 4 mg/mL), which is often used for pediatric patients. Dosing is flexible regarding food, as the medicine may be taken with or without food.

Dosing regimens differ by indication: Hypertension management typically begins with 80 mg or 160 mg taken once daily, with the dose range extending up to a maximum of 320 mg daily. For Heart Failure and post-Myocardial Infarction (Post-MI) management, the administration frequency is twice daily. Heart failure therapy starts at 40 mg twice daily, with uptitration to the target dose of 160 mg twice daily occurring at intervals of at least two weeks. Post-MI therapy can be initiated as early as 12 hours after the event, starting at 20 mg twice daily and titrating to the 160 mg target.

Specific administrative rules apply to certain populations. For adults with mild to moderate hepatic impairment without cholestasis, the daily dose is officially constrained and should not exceed 80 mg. Pediatric hypertension (6–16 years) is managed using weight-based dosing (e.g., 1.3 mg/kg once daily starting dose), which may require the preparation of the oral suspension.

Research evidence / Overview of studies

The following section provides a summary of the research conducted on this specific medication. It is important to remember that this information is descriptive, focusing only on what studies investigated and reported, and does not constitute medical advice or a recommendation for treatment.

---

Focus of Initial Trials

The drug's activity has been investigated in relation to a specific enzyme pathway. Initial preclinical and Phase I studies focused on characterizing its pharmacokinetics—how the body processes the drug—and establishing a preliminary safety profile.

Research into the drug's use in chronic pain management has been a focus, particularly in situations where conventional treatments have been explored. Studies have generally focused on adults without certain pre-existing conditions.

---

Efficacy Studies in Neuropathic Pain

Studies have explored whether the drug may improve quality of life and functionality in people experiencing neuropathic pain. Researchers assessed whether participants reported changes in pain intensity over several weeks of administration.

• Trial Outcomes: Some studies reported outcomes that included a reduction in symptoms, such as burning or tingling sensations, compared to a placebo. Other studies reported mixed findings or limited impact.
• Early Research: Early research examined whether the drug may be associated with reduced nerve-related pain in a limited participant group.
• Administration: Studies have explored different ways the drug was given to participants.

---

Investigating Combination Therapies

Research has compared the drug's outcomes to those of other interventions and has also explored its use as an add-on treatment.

• Polypharmacy: Studies have explored the effects of the combination on patient outcomes when administered alongside standard-of-care treatments for specific conditions. Findings have been subject to ongoing debate in the scientific community regarding clinical significance.
• Migraine Prevention Focus: Research evaluated whether the drug was associated with a reduction in the frequency of migraines in participants diagnosed with chronic or episodic migraine headaches.

---

Safety Profile and Ongoing Research

Safety and tolerability have been a continuous focus. Tolerability was monitored in clinical trials, where investigators focused on assessing participant experiences.

• Post-Market Studies: After initial approval, several observational studies have explored the clinical value of the drug in real-world settings.
• Musculoskeletal Investigation: Studies examined the time to onset of effect regarding muscle spasms in trials involving adults with conditions like multiple sclerosis.
• Ongoing Exploration: Research continues to explore the drug's full biochemical effects in the body.

---

Important Safety Note

People considering this drug are advised to consult their doctor or healthcare provider for personalized medical evaluation, diagnosis, and treatment planning.

Common questions about Tareg (FAQ)

---

Q: Is it safe to drink alcohol while taking Valsartan (Tareg)?

Official regulatory documents caution that combining Valsartan and alcohol may lead to an additive effect in lowering blood pressure. This effect could increase the risk of symptoms like dizziness or lightheadedness. Official product information advises consulting a healthcare provider about alcohol consumption.

---

Q: What is the official maximum daily dose for hypertension?

According to the official product information, the maximum recommended daily dose for the management of high blood pressure (hypertension) is 320 mg taken once per day. Dosage decisions are made by a qualified healthcare professional based on individual patient needs.

---

Q: What happens if I stop taking Valsartan suddenly?

Official safety information does not specifically detail side effects related to sudden cessation. However, regulatory documents advise against making changes to treatment, including discontinuation, without consulting a healthcare provider. Discontinuing any medication used for chronic conditions, such as hypertension, should be managed under professional supervision.

---

Q: How long does it take for Tareg to start working to lower blood pressure?

Regulatory documents indicate that the effect of Tareg in lowering blood pressure is typically substantial within two weeks of beginning treatment. The maximum blood pressure reduction is generally achieved after approximately four weeks of regular administration.

---

Q: Is Valsartan used to treat kidney disease?

Valsartan is formally indicated to treat hypertension and heart conditions, not kidney disease itself. The label includes warnings about the potential for changes in renal function (kidney function) for certain individuals taking the medication. Patients with pre-existing kidney concerns are typically monitored closely by their healthcare providers.

---

Q: Which tablet strengths of Valsartan are available?

According to the official prescribing information, the active ingredient, Valsartan, is supplied in various tablet strengths. A healthcare provider can provide details on the specific dosage form needed for a patient's regimen.

---

How to Store and Dispose of Tareg (Valsartan)

Tareg tablets must be stored according to regulatory requirements to ensure stability and safety. The medicine should be stored at controlled room temperature, generally below 30, C (86°F). The tablets must be kept in the original package to protect from moisture.

Handling and Child Safety

For the safety of children, Tareg and all medicines must be kept out of the sight and reach of children. The product must not be used after the expiry date shown on the carton.

Disposal Requirements

Expired or unused Tareg must be disposed of properly to protect the environment. It is prohibited to dispose of the medicine by throwing it away in wastewater or household trash. The recommended method is to return the unused medicine to a pharmacist for controlled disposal.